Across TCGA pan-cancer cohorts, POTEH Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated POTEH data layer compared with 16 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher POTEH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POTEH expression acts as an unfavorable survival marker.
BLCA, PAAD, and SKCM are the cancer types where POTEH Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.